Global Mycoplasma Testing in Clinical Market – Industry Trends and Forecast to 2030

Analyse et taille du marché des tests de mycoplasmes dans le domaine clinique

Selon le CDC, le nombre de décès dus à des maladies chroniques des voies respiratoires inférieures sera de 152 657 en 2021. Le nombre de décès dus à des maladies respiratoires, à des maladies pulmonaires et à la tuberculose a augmenté et ces chiffres devraient encore augmenter dans les années à venir, alimentant la croissance du marché des tests de mycoplasmes sur le marché clinique. En outre, les principaux acteurs du marché prévoient une augmentation de la demande de diagnostics améliorés pour les thérapies non pulmonaires, ce qui stimulera le marché mondial dans un avenir proche.

Français Data Bridge Market Research analyse que le marché des tests de mycoplasmes sur le marché clinique, qui était de 295,06 millions USD en 2022, devrait atteindre 526,23 millions USD d'ici 2030, à un TCAC de 7,5 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché clinique des tests de mycoplasmes  

Définition du marché

Un test de dépistage des mycoplasmes permet d'identifier une infection active ou récente à mycoplasmes, un type d'infection bactérienne. Le test peut être effectué de différentes manières en fonction de la suspicion, car il existe différents types d'infections à mycoplasmes. Le mycoplasme le plus courant est M. pneumoniae, qui provoque des infections des voies respiratoires supérieures et peut être testé à l'aide d'un échantillon de sang. D'autres tests de dépistage des mycoplasmes peuvent nécessiter la collecte de divers types d'échantillons, tels que des expectorations, du liquide articulaire, des liquides corporels, des échantillons de tissus ou un prélèvement génital.

Tests de mycoplasmes dans la dynamique du marché clinique

Conducteurs

• Augmenter les investissements en R&D

L’augmentation des coûts de recherche et des investissements en R&D des entreprises clés devrait encourager ces dernières à adopter des outils de test des mycoplasmes hautement efficaces. Par exemple, Bristol-Myers Squibb a commencé à investir dans le développement de médicaments expérimentaux pour soutenir les essais cliniques. De plus, avec l’introduction des biosimilaires et les investissements lucratifs en R&D qui en résultent, il est devenu essentiel de réaliser des tests de sécurité pour garantir qu’un produit répond aux normes d’efficacité, de sécurité et de santé publique globale. Merck KGaA a étendu son empreinte de fabrication aux États-Unis en décembre 2020, en investissant plus de 45,6 millions USD (40 millions EUR) dans ses installations de production du Massachusetts et du New Hampshire. Les sites ont été conçus pour produire une variété de produits de fabrication biopharmaceutique tout en augmentant la capacité de production de l’entreprise. Cela devrait encore améliorer la pénétration des outils de test des mycoplasmes.

• Inquiétudes croissantes concernant la contamination des cultures cellulaires

Le problème le plus courant dans les laboratoires de culture cellulaire est la contamination. Les contaminations des cultures cellulaires sont classées en deux types : la contamination chimique et la contamination biologique. Les impuretés, les sérums, l'eau et les endotoxines font partie des contaminants chimiques. Divers tests, notamment les tests de détection des mycoplasmes, sont également utilisés pour détecter la contamination.

Opportunités

• Mondialisation des essais cliniques

The primary reasons pharmaceutical and biopharmaceutical companies choose to outsource clinical trials and R&D are cost efficiency, ease of patient recruitment, lower operating costs, and less stringent regulatory frameworks than those found in the United States and Western Europe. Aside from cost savings, sponsors cite improved quality and reduced time to market as key reasons for outsourcing business functions to CROs, CDMOs, and CMOs.

Restraints/Challenges

• High cost of instruments

The high cost of instruments, as well as the lengthy and laborious detection process, are expected to limit the growth of the mycoplasma testing in clinical market during the forecast period.

This mycoplasma testing in clinical market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the mycoplasma testing in clinical market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, Liofilchem S.r.l launched the AF Genital System, VTM, Lockable contact plates with the improved configuration used for microbial testing. This product improvement assisted the company in increasing its revenue.
• In 2020, BioMérieux SA announced the launch of the biofire mycoplasma test for mycoplasma detection in biopharmaceutical products. This initiative aided the company in expanding its product usage in the biotherapeutics market.

Global Mycoplasma Testing in Clinical Market Scope

The mycoplasma testing in clinical market is segmented on the basis of products, technique, application, disease area and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

• Kits and Reagents
• Instruments
• Services

 Technique

• Microbial Culture Techniques/Direct Assay
• Polymerase Chain Reaction
• ELISA
• DNA Staining/Indirect Assay
• Enzymatic Methods

 Application

• Cell Line Testing
• Virus Testing

 Disease Area

• Respiratory
• Urogenital
• Gastrointestinal
• Musculoskeletal
• Cardiovascular
• Others

 End User

• Diagnostic Laboratories
• Hospitals

Mycoplasma Testing in Clinical Market Regional Analysis/Insights

The mycoplasma testing in clinical market is analyzed and market size insights and trends are provided by country, products, technique, application disease area and end user as referenced above.

The countries covered in the mycoplasma testing in clinical market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the mycoplasma testing in clinical market because of repeated purchases of consumables for the detection of mycoplasma in cell culture, the kits and reagents segment is expected to grow at the fastest rate as well.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to increased demand for effective testing, the kits and reagents segment in Germany is dominating the mycoplasma testing in clinical market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The mycoplasma testing in clinical market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for mycoplasma testing in clinical market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the mycoplasma testing in clinical market. The data is available for historic period 2011-2021.

Competitive Landscape and Mycoplasma Testing in Clinical Market Share Analysis

The mycoplasma testing in clinical market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to mycoplasma testing in clinical market.

Some of the major players operating in the mycoplasma testing in clinical market are:

• AB ANALITICA s.r.l. (Italy)
• BIOMÉRIEUX (France)
• ELITechGroup (France)
• Liofilchem S.r.l. (Italy)
• Agilent Technologies, Inc. (U.S.)
• PromoCell GmbH (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• OSANG Healthcare (South Korea)
• Sacace Biotechnologies Srl (Italy)
• Lonza (Switzerland)
• Merck KGaA (Germany)
• Seegene Inc. (South Korea)
• Clongen Laboratories, LLC (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Charles River Laboratories (U.S.)
• Bionique Testing Laboratories LLC (U.S.)
• ZEAKON Diagnostics (India)

SKU-44726